Abstract: The invention relates generally to the field of nucleic acids and more particularly to aptamers that bind to TFPI, which are useful as therapeutics in and diagnostics of bleeding disorders and/or other diseases or disorders in which TFPI has been implicated. In addition, the TFPI aptamers may be used before, during and/or after medical procedures to reduce complications or side effects thereof. The invention further relates to materials and methods for the administration of aptamers that bind to TFPI.

Abstract: The invention relates generally to the field of nucleic acids and more particularly to aptamers that bind to TFPI, which are useful as therapeutics in and diagnostics of bleeding disorders and/or other diseases or disorders in which TFPI has been implicated. In addition, the TFPI aptamers may be used before, during and/or after medical procedures to reduce complications or side effects thereof. The invention further relates to materials and methods for the administration of aptamers that bind to TFPI.

Abstract: Hemophilia treatment by the inhalation of coagulation factors. Dry powder Factor IX is aerosolized to a mass median aerodynamic diameter of 4 ?m or less, with at least 90% monomer content, at least 80% activity level, and 10% water or less. The aerosol is slowly, and deeply inhaled into the lung, and followed by a maximal exhale.

Abstract: The invention relates to the formulation, dosing, administration and use of an aptamer antagonist therapeutic that binds to von Willebrand Factor.

Abstract: The present teachings relate to the field of anti-inflammatory substances and more particularly to compounds that are useful for the treatment of scleritis, a scleritis symptom, or a scleritis-related disorder. In one aspect, methods of treating scleritis, a scleritis symptom, or a scleritis-related disorder generally include administering to a subject a compound of Formula I: or a pharmaceutically acceptable salt, hydrate or ester thereof, wherein W1, W2, R1, L, X, Y, Z, and n1 are defined as described herein.

Abstract: The present invention relates to methods and compositions for the modulation of restenosis and stenosis characterized by constrictive vascular remodeling and neointimal formation, in a subject, by administering a P-selectin antagonist. The invention further provides methods for modulating leukocyte recruitment, cell to cell adhesion, and cell adhesion to blood vessels in a subject by administering soluble P-selectin ligand, an anti-P-selectin ligand antibody, or an anti-P-selectin antibody. The invention also provides methods for identifying compounds capable of modulating restenosis.

Abstract: The present invention relates to methods and compositions for the modulation thrombosis, in a subject, by administering a P-selectin antagonist. The invention further provides methods for modulating leukocyte recruitment, cellular migration, leukocyte rolling velocity, intercellular adhesion, and cell adhesion to blood vessels in a subject by administering soluble P-selectin ligand or fragments thereof, an anti-P-selectin ligand antibody, or an anti-P-selectin antibody. The invention also provides methods for identifying compounds capable of modulating thrombosis.

Abstract: The present invention relates to methods and compositions for the reduction or prevention of damage to tissue or organs, e.g., the brain, caused by reperfusion following ischemia, e.g., stroke. The present invention also provides methods and compositions for the reduction of the size of infarcts resulting from ischemia and/or reperfusion, in a subject, by administering a P-selectin antagonist. The invention further provides methods for modulating, e.g., attenuating, leukocyte rolling, intercellular adhesion, and cell adhesion to blood vessels in a subject by administering soluble P-selectin ligand or fragments thereof, an anti-P-selectin ligand antibody, or an anti-P-selectin antibody. The invention also provides methods for identifying compounds capable of reducing or preventing damage to tissue or organs caused by ischemic disorders and reperfusion injury.

Abstract: Provided by the present invention are novel compositions and methods for obtaining highly concentrated, liquid, and lyophilized preparations of factor IX suitable for storage and administration.

Abstract: A composition comprising a pharmaceutically acceptable admixture of an osteogenic protein; a porous particulate polymer matrix; and an osteogenic protein-sequestering amount of blood clot.

Abstract: The present invention provides a novel method for preventing deep vein thrombosis comprising the administration of lipoxygenase inhibitors of Formula I ##STR1##

Abstract: The present invention provides a novel method for preventing deep vein thrombosis comprising the adminstration of lipoxygenase inhibitors of Formula I ##STR1##

Abstract: The present invention provides a novel methoda for preventing deep vein thrombosis comprising the administration of lipoxygenase inhibitors of Formula I ##STR1##